Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
Orphanet J Rare Dis. 2019 Jan 10;14(1):12
A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
BMC Cancer. 2019 Jan 03;19(1):2
A National French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing.
Eur J Hum Genet. 2018 Dec 14;:
Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis.
J Clin Med. 2018 Dec 04;7(12):
[Towards an harmonization of diagnosis by NGS of neuromuscular diseases - Actions of the Molecular Genetics sub-group of FILNEMUS].
Med Sci (Paris). 2018 Nov;34 Hors série n°2:20-22
Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.
BMC Cancer. 2018 Oct 23;18(1):1031
Med Decis Making. 2018 Oct;38(7):767-777
Methods Mol Biol. 2018;1828:489-496
Pharmacotherapy versus surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
BJU Int. 2018 Aug 16;:
Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions.
J Natl Cancer Inst. 2018 Jul 19;:
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.